As a Free StocksGuide user, you can view scores for all 7,085 stocks worldwide.
6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
6 Analysts have issued a ZIOPHARM Oncology, Inc. forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 0.01 0.01 |
0%
0%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -4.07 -4.07 |
43%
43%
|
|
| EBIT (Operating Income) EBIT | -4.07 -4.07 |
45%
45%
|
|
| Net Profit | -4.03 -4.03 |
66%
66%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline include Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
| Head office | United States |
| CEO | Dale Hogue |
| Employees | 1 |
| Founded | 2003 |
| Website | alaunos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


